Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy

Fig. 2

Overall Survival for the Six Subgroups of Patients with Stage IIB/C and Stage IIIA Colon Cancer. The 5-year OS are 84.1 % for stage IIIA plus chemotherapy, 70.8 % for stage IIB/C with ≥ 12 LNs plus chemotherapy, 53.9 % for stage IIB/C < 12 LNs plus chemotherapy, 49.5 % for stage IIIA without chemotherapy, 43.7 % for stage IIB/C ≥ 12 LNs without chemotherapy, and 27.7 % for stage IIB/C < 12 LNs without chemotherapy (P < 0.0001). The median survival has not been reached by the end of follow up (132 months) for stage IIIA with chemotherapy, 122.6 months for stage IIB/C, ≥ 12 LNs with chemotherapy, 72.5 months for stage IIB/C, < 12 LNs with chemotherapy, 58.9 months for stage IIIA without chemotherapy, 46.5 months for stage IIB/C, ≥ 12 LNs without chemotherapy, and 23.0 months for stage IIB/C, < 12 LNs without chemotherapy

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us